Grace Therapeutics (GRCE) Stock Analysis

What Grace Therapeutics does

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

Key metrics

ETFs linked to GRCE

Broad-market and Healthcare sector ETFs an investor holding Grace Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GRCE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Grace Therapeutics?

Grace Therapeutics trades under the ticker GRCE on NASDAQ.

Which exchange is GRCE listed on?

GRCE is listed on NASDAQ.

What sector does Grace Therapeutics operate in?

Grace Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GRCE in a portfolio?

PortView shows GRCE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.